Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Симптоматическая фармакотерапия стабильной ишемической болезни сердца: принципы точной настройки
Перепеч Н.Б. Симптоматическая фармакотерапия стабильной ишемической болезни сердца: принципы точной настройки. Consilium Medicum. 2018; 20 (12): 8–14. DOI: 10.26442/20751753.2018.12.000052
________________________________________________
Perepech N.B. Symptomatic pharmacotherapy of stable ischemic heart disease: principles of adjustment. Consilium Medicum. 2018; 20 (12): 8–14. DOI: 10.26442/20751753.2018.12.000052
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье обсуждаются действующие рекомендации по фармакотерапии стабильной ишемической болезни сердца. Приводятся основные положения «бриллиантового» подхода к персонализации симптоматической терапии стабильной стенокардии с обоснованием выбора антиангинальных лекарственных средств в зависимости от клинического и патофизиологического фенотипов больного. Рассматриваются аспекты комбинированной терапии стабильной стенокардии и фиксированные комбинации антиангинальных лекарственных препаратов.
Ключевые слова: стабильная стенокардия, антиангинальные препараты, фиксированные комбинации, персонализация фармакотерапии.
Ключевые слова: стабильная стенокардия, антиангинальные препараты, фиксированные комбинации, персонализация фармакотерапии.
________________________________________________
The article discusses the existing guidelines on stable ischemic heart disease pharmacotherapy. The main principles of approach to personalization of stable angina symptomatic therapy with rationale for antianginal medications choice depending on clinical and pathophysiological phenotypes of the patient are discussed. Aspects of combined therapy for stable angina and use of antianginal medications fixed combinations are presented.
Key words: stable angina, antianginal medications, fixed combinations, pharmacotherapy personalization.
Key words: stable angina, antianginal medications, fixed combinations, pharmacotherapy personalization.
Полный текст
Список литературы
1. Boden WE, O'Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356 (15): 1503–16.
2. Al-Lamee R, Thompson D, Dehbi HM et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018; 391 (10115): 31–40.3. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003.
4. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281–344.
5. Fox K, Ford I, Steg PG et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371 (12): 1091–9.
6. Vidal-Petiot E, Ford I, Greenlaw N et al.; CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388 (10056): 2142–52.
7. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH 2013 ESC guidelines for the management of arterial hypertension: the Task Force on the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 00: 1–98. DOI: 10.1093/eurheartj/ehy339
8. Manolis AJ, Poulimenos LE, Ambrosio G et al. Medical treatment of stable angina: A tailored therapeutic approach. Int J Cardiol 2016; 220: 445–53.
9. Ferrari R, Camici PG, Crea F et al. Expert consensus document: a “diamond” approach to personalized treatment of angina. Nat Rev Cardiol 2018; 15 (2): 120–32.
10. Fox K, Ford I, Steg PJ et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16.
11. Fox K, Ford I, Steg PJ et al. Relationship between Ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left-ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2337–45.
12. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
13. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Effects of ivabradine in patients with stable angina receiving b-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168 (2): 789–94.
14. Amosova E, Andrejev E, Zaderey I et al. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther 2011; 25 (6): 531–7.
15. Divchev D, Stöckl G; study investigators. Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice. Cardiol Ther 2017; 6 (2): 239–49.
16. Weber F, Schneider H, von Arnim T, Urbaszek W. Heart rate variability and ischemia in patients with coronary heart disease and stable angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study. Eur Heart J 1999; 20 (1): 38–50.
17. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsFox KM1; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–9.
________________________________________________
2. Al-Lamee R, Thompson D, Dehbi HM et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018; 391 (10115): 31–40.
3. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003.
4. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281–344.
5. Fox K, Ford I, Steg PG et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371 (12): 1091–9.
6. Vidal-Petiot E, Ford I, Greenlaw N et al.; CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388 (10056): 2142–52.
7. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH 2013 ESC guidelines for the management of arterial hypertension: the Task Force on the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 00: 1–98. DOI: 10.1093/eurheartj/ehy339
8. Manolis AJ, Poulimenos LE, Ambrosio G et al. Medical treatment of stable angina: A tailored therapeutic approach. Int J Cardiol 2016; 220: 445–53.
9. Ferrari R, Camici PG, Crea F et al. Expert consensus document: a “diamond” approach to personalized treatment of angina. Nat Rev Cardiol 2018; 15 (2): 120–32.
10. Fox K, Ford I, Steg PJ et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16.
11. Fox K, Ford I, Steg PJ et al. Relationship between Ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left-ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2337–45.
12. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
13. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Effects of ivabradine in patients with stable angina receiving b-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168 (2): 789–94.
14. Amosova E, Andrejev E, Zaderey I et al. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther 2011; 25 (6): 531–7.
15. Divchev D, Stöckl G; study investigators. Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice. Cardiol Ther 2017; 6 (2): 239–49.
16. Weber F, Schneider H, von Arnim T, Urbaszek W. Heart rate variability and ischemia in patients with coronary heart disease and stable angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study. Eur Heart J 1999; 20 (1): 38–50.
17. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsFox KM1; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–9.
Авторы
Н.Б.Перепеч
ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Россия, Санкт-Петербург, Университетская наб., д. 7/9
nikita_perepech@mail.ru
ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Россия, Санкт-Петербург, Университетская наб., д. 7/9
nikita_perepech@mail.ru
________________________________________________
N.B.Perepech
Saint Petersburg State University. 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9
nikita_perepech@mail.ru
Saint Petersburg State University. 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9
nikita_perepech@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.